rmat: Abstract  ian Heart J. 2017 May - Jun;69(3):393-401. doi: 10.1016/j.ihj.2017.04.001. Epub 2017 Apr 29.  odulation of myocardial energetics: An important cat gents in the multimodal treatment of coronary artery of eart failure.  lal JJ 1, Mishra S <sup>2</sup> .  Author information  ostract  e combined and relative contribution of glucose and fatty acid oxidation geneergy, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting frormance of the heart. Metabolic therapy is relatively a new modality, which it imization of cardiac substrate metabolism. Among the metabolic therapies, the notation are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.  pyright © 2017. Published by Elsevier B.V.	erates myocardial in this metabolic c conditions such a anomaly, by ig in a better functions through trimetazidine and e would like to
odulation of myocardial energetics: An important cat gents in the multimodal treatment of coronary artery ceart failure.  Lal JJ <sup>1</sup> , Mishra S <sup>2</sup> .  Author information  Destract  Description of eardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	tegory of disease and his metabolic conditions such a anomaly, by ig in a better functions through trimetazidine and a would like to
odulation of myocardial energetics: An important cat gents in the multimodal treatment of coronary artery of eart failure.  lal JJ <sup>1</sup> , Mishra S <sup>2</sup> .  Author information  estract  e combined and relative contribution of glucose and fatty acid oxidation gene ergy, which regulates the cardiac function and efficiency. Any dysregulation is meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the notation are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	tegory of disease and this metabolic conditions such anomaly, by ig in a better functions through trimetazidine and would like to
gents in the multimodal treatment of coronary artery of eart failure.  lal JJ <sup>1</sup> , Mishra S <sup>2</sup> .  Author information  estract  e combined and relative contribution of glucose and fatty acid oxidation generally, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	erates myocardial in this metabolic c conditions such a anomaly, by ig in a better functions through trimetazidine and e would like to
gents in the multimodal treatment of coronary artery of eart failure.  lal JJ <sup>1</sup> , Mishra S <sup>2</sup> .  Author information  estract  e combined and relative contribution of glucose and fatty acid oxidation generally, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	erates myocardial in this metabolic c conditions such a anomaly, by ig in a better functions through trimetazidine and e would like to
Part failure.  Ital JJ <sup>1</sup> , Mishra S <sup>2</sup> .  Author information  Distract  The combined and relative contribution of glucose and fatty acid oxidation generally which regulates the cardiac function and efficiency. Any dysregulation in the meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting formance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the notation of cardiac substrate metabolism. Among the metabolic therapies, the notation are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	erates myocardial in this metabolic c conditions such c anomaly, by ig in a better functions through trimetazidine and e would like to
Author information  estract e combined and relative contribution of glucose and fatty acid oxidation genergy, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we seent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	in this metabolic c conditions such c anomaly, by ig in a better functions through trimetazidine and e would like to
e combined and relative contribution of glucose and fatty acid oxidation genergy, which regulates the cardiac function and efficiency. Any dysregulation is meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the notation of cardiac substrate metabolism. Among the metabolic therapies, the notation are the agents presently available in India. In the present review, we seem the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	in this metabolic c conditions such c anomaly, by ig in a better functions through trimetazidine and e would like to
e combined and relative contribution of glucose and fatty acid oxidation genergy, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we esent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	in this metabolic c conditions such c anomaly, by ig in a better functions through trimetazidine and e would like to
e combined and relative contribution of glucose and fatty acid oxidation genergy, which regulates the cardiac function and efficiency. Any dysregulation in meostasis can adversely affect the function of heart and contribute to cardiac angina and heart failure. Metabolic agents ameliorate this internal metabolic ifting the energy production pathway from free fatty acids to glucose, resulting rformance of the heart. Metabolic therapy is relatively a new modality, which timization of cardiac substrate metabolism. Among the metabolic therapies, the nolazine are the agents presently available in India. In the present review, we esent the metabolic perspective of pathophysiology of coronary artery diseased metabolic therapy by using trimetazidine and ranolazine.	in this metabolic c conditions such c anomaly, by ig in a better functions through trimetazidine and e would like to
YWORDS: Heart failure: Ischemia: Motabolic thoragy: Stable angine: Trimeteridine	o and nourcrandic
YWORDS: Heart failure; Ischemia; Metabolic therapy; Stable angina; Trimetazidine	
IID: 28648439 DOI: <u>10.1016/j.jhj.2017.04.001</u>	
ee full text	
iblication type	
₁kOut - more resources	
nkOut - more resources	
nkOut - more resources	

https://www.ncbi.nlm.nih.gov/pubmed/28648439

How to join PubMed Commons